inotersen
E561115
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
All labels observed (1)
| Label | Occurrences |
|---|---|
| inotersen canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T6005130 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: inotersen Context triple: [Tegsedi, hasInternationalNonproprietaryName, inotersen]
-
A.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
onasemnogene abeparvovec
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Alexion Pharmaceuticals
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: inotersen Target entity description: Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
A.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
onasemnogene abeparvovec
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Alexion Pharmaceuticals
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
antisense oligonucleotide drug
ⓘ
pharmacologic substance ⓘ transthyretin synthesis inhibitor ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| belongsToTherapeuticArea |
neurology
ⓘ
rare diseases ⓘ |
| bindsTo | TTR mRNA in the liver ⓘ |
| contraindication |
history of serious hypersensitivity to inotersen
ⓘ
severe thrombocytopenia ⓘ |
| developedBy | Ionis Pharmaceuticals ⓘ |
| EMAApprovalYear | 2018 ⓘ |
| FDAApprovalYear | 2018 ⓘ |
| hasAdministrationFrequency | once weekly ⓘ |
| hasATCCode | N07XX14 ⓘ |
| hasBackboneModification | phosphorothioate ⓘ |
| hasBlackBoxWarningFor |
glomerulonephritis
ⓘ
thrombocytopenia ⓘ |
| hasChemicalNature | single-stranded antisense oligonucleotide ⓘ |
| hasCommonAdverseEffect |
fatigue
ⓘ
headache ⓘ injection site reactions ⓘ nausea ⓘ |
| hasDosingForm | pre-filled syringe ⓘ |
| hasINN | inotersen ⓘ |
| hasMolecularType | 2′-O-methoxyethyl–modified antisense oligonucleotide ⓘ |
| hasPregnancyCategory | not recommended in pregnancy unless clearly needed ⓘ |
| hasRouteOfAdministration | subcutaneous injection ⓘ |
| hasSeriousAdverseEffect |
glomerulonephritis
ⓘ
immune-mediated reactions ⓘ severe thrombocytopenia ⓘ |
| hasTradeName | Tegsedi ⓘ |
| indication |
hereditary transthyretin-mediated amyloidosis
ⓘ
polyneuropathy of hereditary transthyretin-mediated amyloidosis ⓘ |
| legalStatusInEuropeanUnion | prescription only ⓘ |
| legalStatusInUnitedStates | prescription only ⓘ |
| marketedBy | Akcea Therapeutics ⓘ |
| mechanismOfAction |
RNase H–mediated degradation of TTR mRNA
ⓘ
inhibition of transthyretin protein synthesis ⓘ |
| primarySiteOfAction | liver ⓘ |
| reduces | serum transthyretin concentration ⓘ |
| reducesLevelOf | transthyretin protein ⓘ |
| requiresMonitoringOf |
platelet count
ⓘ
renal function ⓘ |
| requiresRiskManagementProgram | yes ⓘ |
| targets | transthyretin mRNA ⓘ |
| treatsSymptom |
autonomic neuropathy in hATTR
ⓘ
sensorimotor polyneuropathy in hATTR ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: inotersen Description of subject: Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.